These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 31291985

  • 1. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.
    Dama P, Tang M, Fulton N, Kline J, Liu H.
    J Immunother Cancer; 2019 Jul 10; 7(1):175. PubMed ID: 31291985
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia.
    Huang S, Liang C, Zhao Y, Deng T, Tan J, Zha X, Li Y, Chen S.
    Cytometry B Clin Cytom; 2022 Mar 10; 102(2):143-152. PubMed ID: 34913594
    [Abstract] [Full Text] [Related]

  • 5. Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells.
    Corradi G, Forte D, Cristiano G, Polimeno A, Ciciarello M, Salvestrini V, Bandini L, Robustelli V, Ottaviani E, Cavo M, Ocadlikova D, Curti A.
    Front Immunol; 2024 Mar 10; 15():1386517. PubMed ID: 38812504
    [Abstract] [Full Text] [Related]

  • 6. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.
    Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK, Blazar BR.
    Blood; 2011 Apr 28; 117(17):4501-10. PubMed ID: 21385853
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Increased exhausted CD8+ T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with multiple myeloma.
    Tan J, Chen S, Huang J, Chen Y, Yang L, Wang C, Zhong J, Lu Y, Wang L, Zhu K, Li Y.
    Asia Pac J Clin Oncol; 2018 Oct 28; 14(5):e266-e274. PubMed ID: 29943497
    [Abstract] [Full Text] [Related]

  • 9. [Expression and Significance of PD-1, TIM-3 and VISTA on T Cell of Acute Myeloid Leukemia Patients].
    Ge MJ, Xu KL, Xu T, Tang YN, Li ZY, Yan ZL, Sun HY, Cheng H, Zhu F, Sang W, Huang YH, Qiu TT, Li DP.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun 28; 28(3):748-752. PubMed ID: 32552931
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients.
    Wu K, Feng J, Xiu Y, Li Z, Lin Z, Zhao H, Zeng H, Xia W, Yu L, Xu B.
    Int Immunopharmacol; 2020 Mar 28; 80():106122. PubMed ID: 31955066
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.
    Kim HP, Bernard L, Berkowitz J, Nitta J, Hogge DE.
    Cytometry B Clin Cytom; 2012 Sep 28; 82(5):283-94. PubMed ID: 22508650
    [Abstract] [Full Text] [Related]

  • 15. Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.
    Chajuwan T, Kansuwan P, Kobbuaklee S, Chanswangphuwana C.
    Leuk Lymphoma; 2022 Feb 28; 63(2):450-456. PubMed ID: 34585994
    [Abstract] [Full Text] [Related]

  • 16. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT.
    Noviello M, Manfredi F, Ruggiero E, Perini T, Oliveira G, Cortesi F, De Simone P, Toffalori C, Gambacorta V, Greco R, Peccatori J, Casucci M, Casorati G, Dellabona P, Onozawa M, Teshima T, Griffioen M, Halkes CJM, Falkenburg JHF, Stölzel F, Altmann H, Bornhäuser M, Waterhouse M, Zeiser R, Finke J, Cieri N, Bondanza A, Vago L, Ciceri F, Bonini C.
    Nat Commun; 2019 Mar 25; 10(1):1065. PubMed ID: 30911002
    [Abstract] [Full Text] [Related]

  • 17. Immunosuppression of Human Adipose-Derived Stem Cells on T Cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways.
    Zhou K, Guo S, Tong S, Sun Q, Li F, Zhang X, Qiao Y, Liang G.
    Stem Cells Dev; 2018 Sep 01; 27(17):1191-1202. PubMed ID: 29978730
    [Abstract] [Full Text] [Related]

  • 18. Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.
    Kasner MT, Mick R, Jeschke GR, Carabasi M, Filicko-O'Hara J, Flomenberg N, Frey NV, Hexner EO, Luger SM, Loren AW, Mangan JK, Wagner JL, Weiss M, Carroll M, Perl AE.
    Invest New Drugs; 2018 Aug 01; 36(4):657-666. PubMed ID: 29607465
    [Abstract] [Full Text] [Related]

  • 19. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
    Zahran AM, Mohammed Saleh MF, Sayed MM, Rayan A, Ali AM, Hetta HF.
    Cancer Biomark; 2018 Aug 01; 22(3):587-595. PubMed ID: 29843224
    [Abstract] [Full Text] [Related]

  • 20. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
    Sweet K, Komrokji R, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE.
    Clin Cancer Res; 2020 Jan 01; 26(1):54-60. PubMed ID: 31636097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.